1st Quarter - Report

GREENWICH BIOSCIENCES, INC. for GREENWICH BIOSCIENCES, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2018 $80,000 Replaced
1st Quarter - Amendment May 1, 2018 $40,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Introduction of company and development of a FDA approved cannabinoid drug SB 1008: Definition of CBD SB 1276: Definition of authorized medical research SB 1803: Definition of CBD HR 331: Definition of CBD HR 715: Definition of CBD HR 975: Definition of CBD HR 1277: Definition of CBD HR 1823: Definition of CBD HR 1841: Definition of CBD HR 2920: Definition of CBD HR 3530: Definition of CBD

LobbyistCovered position, as disclosed
ALICE P. MEAD —

Contacted: Office of Management & Budget (OMB); White House Office; HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 715 (115th), H.R. 975 (115th), H.R. 1841 (115th), H.R. 3530 (115th), H.R. 1823 (115th), H.R. 331 (115th), H.R. 2920 (115th), H.R. 1277 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.